Edwards Lifesciences (EW) Proxy Filing summary

Executive summary

• Board recommends FOR all five proposals at the 2025 annual meeting, covering nine director nominees, executive compensation, auditor ratification, and U.S. and international employee stock purchase plans.

• Strategy centers on structural heart growth, patient-focused innovation, and corporate impact integrated with business priorities.

Voting matters and shareholder proposals

• Proposal 1 seeks election of nine director nominees; Proposal 2 seeks advisory approval of named executive officer compensation; Proposal 3 seeks ratification of the independent registered public accounting firm.

• Proposals 4 and 5 seek approval of amended and restated employee stock purchase plans for U.S. and international employees, respectively; Board recommends FOR each.

Board of directors and corporate governance

• Board has nine nominees and broad medical technology, healthcare, finance, global operations, governance, and technology experience; 89% of directors are independent.

• Two directors, Leslie C. Davis and David T. Feinberg, joined in 2024, bringing healthcare operations and health technology leadership experience.

• Board skills include innovation, regulatory and compliance, risk management, financial reporting, cybersecurity, human capital, and corporate responsibility oversight.